---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066945"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:41:18.459203+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alector Q1 net loss $40.5M ($0.41/sh); INFRONT-3 data on track for Q4 2025

## Summary
- Net loss of $40.5M ($0.41/sh) vs $36.1M ($0.38/sh) in Q1 2024; collaboration revenue $3.7M (down from $15.9M).
- Cash, cash equivalents, and investments total $354.6M as of March 31, 2025; runway extended into second half of 2027.
- Topline INFRONT-3 Phase 3 data for latozinemab in FTD-GRN expected in Q4 2025; enrollment complete in PROGRESS-AD Phase 2 for AL101.
- Giacomo Salvadore appointed Chief Medical Officer; 2025 guidance reiterated: R&D $175-185M, G&A $55-65M, collab rev $5-15M.
- Advancing preclinical Alector Brain Carrier programs including anti-amyloid beta antibody and GCase enzyme replacement therapy.

## SEC filing metadata
- accession: 0000950170-25-066945
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/0000950170-25-066945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066945
- JSON: https://secwatch.observer/filing/0000950170-25-066945.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.